SLGL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	15 578.00
Average Volume	32 325.00
Market Cap	26.05M
EPS	$0 ( 2024-03-15 )
Next earnings date	( $-0.150 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.930
ATR14	$0.0150 (1.60%)

Sol Gel Technologies Ltd Correlation

10 Most Positive Correlations
CFB	0.849

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sol Gel Technologies Ltd Financials

Annual	2023
Revenue:	$1.55M
Gross Profit:	$1.21M (77.99 %)
EPS:	$-1.010

Q4	2023
Revenue:	$447 000
Gross Profit:	$447 000 (100.00 %)
EPS:	$-0.170

Q3	2023
Revenue:	$213 000
Gross Profit:	$-4.46M (-2 093.43 %)
EPS:	$-0.210

Q2	2023
Revenue:	$594 000
Gross Profit:	$-4.72M (-794.28 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.